2025-01-16 10:48:08
I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
Corporate/ 2023-07-23
I-Mab Announces IND Acceptance for Phase...

Efineptakin alfa in combination with pembrolizumab induced 27.8% ORR in metastatic TNBC patients in a phase 1b/2 trial in South Korea

GenScript Announces Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Kit
Corporate/ 2023-07-23
GenScript Announces Notice of Allowance ...

PISCATAWAY,N.J.,July 28,2021-- GenScript Biotech Corporation ("GenScript",Stock Code: 1548.HK),aworld-leading life sciences resear...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release